Understanding the Mifepristone Legal Battle: A Guide to FDA Authority and Regulatory Preemption

Overview

The ongoing legal dispute over mifepristone—a medication used for abortion—has become a landmark case testing the limits of federal regulatory power. In early 2023, a Texas federal judge suspended the FDA's long-standing approval of mifepristone, prompting a series of appeals that reached the U.S. Supreme Court. The Court then issued a temporary pause on a lower court's decision that would have banned mail-order distribution of the drug. This guide unpacks the legal mechanics, the roles of key players, and the broader implications for drug regulation. By the end, you'll understand who decides how mifepristone is prescribed and dispensed, and why that matters for the FDA's authority.

Prerequisites

To follow this guide, you should be familiar with:

• U.S. legal system basics – the federal court hierarchy (district, appeals, Supreme Court) and the concept of injunctions.
• FDA drug approval process – how the FDA evaluates safety and efficacy, and what REMS (Risk Evaluation and Mitigation Strategies) are.
• Abortion law context – the 2022 Dobbs decision that overturned Roe v. Wade, returning abortion regulation to states.

No prior legal expertise is needed, but a willingness to navigate regulatory terminology helps.

Step-by-Step: The Mifepristone Case Unpacked

Step 1: Understand the FDA's Role and Mifepristone's History

Mifepristone was first approved by the FDA in 2000 for medication abortion (up to 7 weeks of pregnancy). In 2016 and 2021, the FDA relaxed restrictions: allowing telemedicine consultations and mail-order dispensing. These changes relied on the agency's scientific judgment that the drug's benefits outweigh risks when used as directed. The FDA's authority to conditionally approve drugs and modify distribution rules stems from the Federal Food, Drug, and Cosmetic Act.

Key fact: The FDA determined that in-person dispensing requirements were unnecessary for safety, enabling wider access—a decision that later became a legal flashpoint.

Step 2: Trace the Legal Challenge

In November 2022, a group of anti-abortion doctors and organizations sued the FDA in the U.S. District Court for the Northern District of Texas. The plaintiffs argued that the FDA exceeded its authority by approving mifepristone and later removing safety restrictions, citing the Comstock Act (an 1873 law that prohibits mailing abortion-related materials).

• District court ruling (April 7, 2023): Judge Matthew Kacsmaryk issued a nationwide injunction suspending the FDA's approval of mifepristone—effectively banning the drug across the U.S.
• Fifth Circuit appeals court (April 12, 2023): The appeals court partially blocked the district ruling but allowed restrictions to be reinstated: banning mail-order distribution and requiring three in-person visits.

Step 3: The Supreme Court's Emergency Pause

The Biden administration and the drug's manufacturer, Danco Laboratories, appealed to the Supreme Court, asking for a stay of the Fifth Circuit's order. On April 21, 2023, the Supreme Court granted a temporary administrative stay, pausing the appeals court's restrictions and preserving the status quo (mail-order allowed, no extra visits). The Court gave itself until the end of April 24 to decide whether to keep the pause in place while the case proceeds.

What the pause means: The FDA's current regulations remain in effect. Patients can still receive mifepristone by mail after a telemedicine consultation, and no additional in-person requirements are imposed. The Court's eventual decision could clarify whether the FDA's authority preempts state-level restrictions.

Step 4: Analyze the Core Legal Question – Preemption

As Laurie Sobel of KFF explained: “The fundamental question is: Who gets to regulate mifepristone? Can a state go further than the FDA? Is the FDA the floor or the ceiling?” This is a classic preemption issue: federal law (FDA decisions) normally overrides conflicting state law. But after Dobbs, some states have passed near-total abortion bans. If the FDA says a drug is safe enough for mail-order, can a state like Texas still require in-person dispensing?

The Supreme Court’s eventual ruling will either reaffirm the FDA's primacy or open the door for states to impose additional barriers beyond federal minimums. That outcome will affect not just mifepristone but all FDA-regulated drugs—from opioids to birth control.

Common Mistakes to Avoid

• Assuming the case is solely about abortion. While abortion is the context, the legal question is about federal versus state regulatory power. The FDA's authority to set nationwide drug safety standards is at stake.
• Confusing the Comstock Act with modern laws. The 1873 Comstock Act has rarely been enforced; courts must decide if it still applies to abortion medications. Many legal scholars argue it does not bar mailing mifepristone under current interpretations.
• Overlooking the FDA's scientific discretion. Courts typically defer to FDA expert judgment. The Texas district judge’s refusal to defer was unusual and may be reversed on appeal.
• Thinking the Supreme Court pause is a final ruling. It’s only an emergency order to maintain stability while litigation continues. The full merits have not been decided.

Summary

This guide has traced the mifepristone legal battle from FDA approval through the Supreme Court’s emergency pause. The core conflict is about preemption: whether the FDA’s safety decisions set a national floor that states cannot undercut. As the case unfolds, it will shape not only abortion access but the balance of power between federal regulators and state governments. Understanding these steps helps demystify a complex legal fight with far-reaching consequences for public health and regulation.